BioGaia AB (publ) (FRA:BGLA)

Germany flag Germany · Delayed Price · Currency is EUR
9.62
-0.02 (-0.21%)
At close: Sep 30, 2025
-0.21%
Market Cap980.90M
Revenue (ttm)128.92M
Net Income (ttm)25.67M
Shares Outn/a
EPS (ttm)0.25
PE Ratio38.22
Forward PE29.19
Dividend0.63 (6.42%)
Ex-Dividend DateMay 8, 2025
Volumen/a
Average Volume1
Open9.62
Previous Close9.64
Day's Range9.62 - 9.62
52-Week Range8.36 - 12.00
Betan/a
RSI55.88
Earnings DateOct 21, 2025

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablet... [Read more]

Industry Pharmaceutical Preparations
Founded 1990
Employees 225
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BGLA
Full Company Profile

Financial Performance

In 2024, BioGaia AB's revenue was 1.42 billion, an increase of 9.73% compared to the previous year's 1.30 billion. Earnings were 351.39 million, a decrease of -3.82%.

Financial numbers in SEK Financial Statements

News

There is no news available yet.